C5 and Alzheimer disease: In Alzheimer’s disease, antibody-mediated suppression of C1q has been shown to ameliorate synapse removal in TauP301S transgenic mice,66 while C5 inhibitors are currently being trialled for ALS (ID: NCT0424845).